摘要
目的:探讨螺内酯联合贝那普利治疗慢性充血性心力衰竭的临床疗效及安全性。方法:将104例慢性充血性心力衰竭患者根据治疗适应证和家属意见分为两组,每组52例。治疗组接受螺内酯联合贝那普利治疗,对照组仅给予贝那普利。观察24周,比较两组治疗前后心功能及血生化各项指标的变化。结果:治疗组总有效率明显高于对照组(P<0.05);治疗后治疗组LVEDD、LVESD和LVEF改善情况均优于对照组,两组比较差异有统计学意义(P<0.05)。结论:螺内酯联合贝那普利治疗慢性充血性心力衰竭,可改善患者的心功能。
Objective：To observe the clinical therapeutic effect of spironolactone plus benazepril in the treatment of chronic congestive heart failure （CHF）. Methods： According to the treatment indications and families advices, 104 cases chronic congestive heart failure were divided into treatment group and control group. 52 cases of treatmerit group were treated with spironolactone plus benazepril, 52 cases of control group with benazepril for 24 weeks on the basis of conventional drugs. Results：The total effecrive rate in the treatment group was significantly higher than in control group （P 〈0. 05）. The ejection fraction in both groups had significant improvement as compared with before treatment, with the treatment group showing a better improvement than in control group, there were significant differences between the two groups （ P 〈 0. 05 ）.Conclusion：Curative effect is dependable for spironolaetone plus benazepril treating chronie congestive heart failure, it call improve prognosis and raise life quality of the patients,it is worthy of popularization and application.
